Literature DB >> 10783967

Histopathologic study of presumed parafoveal telangiectasis.

J D Gass.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10783967     DOI： 10.1097/00006982-200002000-00028

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  10 in total

1.  Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice.

Authors:  Jing Hua; Karen I Guerin; Jing Chen; Shaday Michán; Andreas Stahl; Nathan M Krah; Molly R Seaward; Roberta J Dennison; Aimee M Juan; Colman J Hatton; Przemyslaw Sapieha; David A Sinclair; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-25       Impact factor: 4.799

2.  Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density.

Authors:  Eric K Chin; Dae Yu Kim; Allan A Hunter; Suman Pilli; Machelle Wilson; Robert J Zawadzki; John S Werner; Susanna S Park
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-02       Impact factor: 4.799

3.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2010-08-03       Impact factor: 12.079

4.  Demographic features of idiopathic macular telangiectasia in Japanese patients.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Akira Ojima; Hiroshi Oyamada; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2012-01-06       Impact factor: 2.447

5.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.

Authors:  Michael I Dorrell; Edith Aguilar; Ruth Jacobson; Oscar Yanes; Ray Gariano; John Heckenlively; Eyal Banin; G Anthony Ramirez; Mehdi Gasmi; Alan Bird; Gary Siuzdak; Martin Friedlander
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

6.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

7.  Optical Coherence Tomography Angiography of Macular Telangiectasia Type 2 with Associated Subretinal Neovascular Membrane.

Authors:  Victor M Villegas; Jaclyn L Kovach
Journal:  Case Rep Ophthalmol Med       Date:  2017-11-09

8.  Surgical Outcomes in Macular Telangiectasia Type 2-Related Macular Holes: A Report on Four Patients.

Authors:  Kinza T Ahmad; Joseph Chacko; Ahmed B Sallam; David B Warner; Sami H Uwaydat
Journal:  Case Rep Ophthalmol Med       Date:  2020-12-07

9.  Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization

Authors:  Müge Çoban Karataş; Gürsel Yılmaz; Aslıhan Yüce Sezen; Çağla Sarıtürk
Journal:  Turk J Ophthalmol       Date:  2022-02-23

Review 10.  When is macular edema not macular edema? An update on macular telangiectasia type 2.

Authors:  Lihteh Wu
Journal:  Taiwan J Ophthalmol       Date:  2015-11-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.